PROCEPT BioRobotics recently reported two major milestones in its WATER IV prostate cancer program, completing enrollment in the randomized WATER IV RP trial comparing Aquablation therapy with radical ...

Chicago Capital added 969,592 shares of PROCEPT BioRobotics, an estimated $27.32 million trade based on the average share price in the first quarter of 2026. Quarter-end position value rose by $16.57 ...

The WATER IV AS trial aims to assess Aquablation as earlier intervention for men on active surveillance Procept BioRobotics has received a second FDA investigational device exemption (IDE) to allow ...

Procept BioRobotics (Nasdaq:PRCT) announced that it received FDA investigational device exemption (IDE) for a second ...

PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the best robotic surgery stocks to buy. PROCEPT BioRobotics ...

Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.

Key Points Interested in Ouster, Inc.? Here are five stocks we like better. As AI moves from the digital world into the ...

PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the American Urological Association (AUA) Guidelines for the management of lower urinary tract symptoms (LUTS) attributed to ...

Stephanie Piazzola, I cover medical devices at BofA. And next up, we have PROCEPT BioRobotics. We have Larry Wood, CEO; and Kevin Waters, CFO. So thanks both for being here today. Maybe we can start ...

PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative ...

Good afternoon, and welcome to PROCEPT BioRobotics First Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. I would now like ...